Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 2h ago
0mins
Source: PRnewswire
- Global Expansion Milestone: Zylox-Tonbridge has entered into an acquisition agreement with Germany’s Optimed, aiming to accelerate the global adoption of innovative vascular solutions by integrating R&D, manufacturing, and commercialization platforms, which is expected to significantly enhance market penetration.
- Operational Synergies: The acquisition will integrate the sales networks of both companies, leveraging Optimed’s long-standing customer relationships in over 70 countries to improve product time-to-market and strengthen competitiveness in the European market.
- Efficient R&D Capabilities: Zylox-Tonbridge will fully unlock its R&D and manufacturing synergies in China and Germany, ensuring the provision of high-quality, reliable innovative medical solutions to meet evolving customer needs in global markets.
- Leadership Integration: Following the acquisition, Optimed’s CEO Rüdiger Hausherr will continue to lead Optimed and report to Zylox-Tonbridge’s Chairman Jonathon Zhong Zhao, ensuring strategic alignment and collaborative growth between the two companies.
Analyst Views on 02190
Wall Street analysts forecast 02190 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02190 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company’s fundamentals.
Wall Street analysts forecast 02190 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02190 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company’s fundamentals.
Current: 25.620
Current: 25.620
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
